ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, today announced that it has appointed Rhonda Robb as its new Chief Operating Officer. She will report to Scott Ward, CSI Chairman, President and Chief Executive Officer.
Robb formerly served as Vice President and General Manager of the Heart Valve Therapies business at Medtronic. In that role, she was responsible for the transcatheter and surgical valve franchises. Previously, Robb held additional leadership positions in Medtronic’s Coronary, Peripheral and Cardiac Rhythm businesses. She has strong experience leading complex businesses, growing new markets, extensive commercial experience, and a strong track record of building teams and product portfolios that have improved the quality of care for patients with cardiovascular disease.
“Rhonda is a dynamic and talented executive with extraordinary experience in driving innovation and growth in medical technology,” said Ward. “She has the leadership ability, executional strengths and experience to further build CSI, and achieve our ambitious growth goals, as well as guide the expansion of the company’s peripheral and coronary franchises.”
Said Robb, “I am excited to have the opportunity to join CSI and I look forward to working with the team to improve the health of people with coronary and peripheral artery disease.”
Robb earned a bachelor’s degree from the University of Minnesota and a master’s in business administration from the Carlson School of Management at the University of Minnesota.
Robb replaces Kevin Kenny who will depart from CSI at the end of January.
Said Ward, “As Chief Operating Officer, Kevin has made many contributions to the growth and success of CSI. We are grateful for his commitment to our mission and wish him well in his future endeavors.”
About Cardiovascular Systems, Inc.
Cardiovascular Systems,
Inc., based in St. Paul, Minn., is a medical device company focused on
developing and commercializing innovative solutions for treating
vascular and coronary disease. The company’s Orbital Atherectomy Systems
treat calcified and fibrotic plaque in arterial vessels throughout the
leg and heart in a few minutes of treatment time, and address many of
the limitations associated with existing surgical, catheter and
pharmacological treatment alternatives. The U.S. FDA granted the first
510(k) clearance for the use of the Orbital Atherectomy System in
peripheral arteries in August 2007. In October 2013, the company
received FDA approval for the Coronary Orbital Atherectomy System. To
date, over 340,000 of CSI’s devices have been sold to leading
institutions across the United States. For more information, visit the
company’s website at www.csi360.com.